Collplant Biotechnologies Ownership
| CLGN Stock | USD 4.48 0.23 5.41% |
Shares in Circulation | First Issued 2014-06-30 | Previous Quarter 11.5 M | Current Value 11.5 M | Avarage Shares Outstanding 133.2 M | Quarterly Volatility 777.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Collplant |
Collplant Stock Ownership Analysis
The book value of the company was currently reported as 2.48. The company recorded a loss per share of 1.53. Collplant Biotechnologies last dividend was issued on the 21st of November 2016. The entity had 2:3 split on the 21st of November 2016. CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. CollPlant Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people. For more info on Collplant Biotechnologies please contact Yehiel Tal at 972 73 232 5600 or go to https://www.collplant.com.Besides selling stocks to institutional investors, Collplant Biotechnologies also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Collplant Biotechnologies' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Collplant Biotechnologies' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Collplant Biotechnologies Quarterly Liabilities And Stockholders Equity |
|
About 10.0% of Collplant Biotechnologies are currently held by insiders. Unlike Collplant Biotechnologies' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Collplant Biotechnologies' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Collplant Biotechnologies' insider trades
Collplant Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Collplant Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Collplant Biotechnologies backward and forwards among themselves. Collplant Biotechnologies' institutional investor refers to the entity that pools money to purchase Collplant Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Parallel Advisors, Llc | 2024-06-30 | 3.3 K |
Collplant Biotechnologies Outstanding Bonds
Collplant Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Collplant Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Collplant bonds can be classified according to their maturity, which is the date when Collplant Biotechnologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Collplant Biotechnologies Corporate Filings
6K | 27th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 4th of April 2024 Other Reports | ViewVerify | |
13A | 13th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with Collplant Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Collplant Stock
Moving against Collplant Stock
| 0.88 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.86 | GILD | Gilead Sciences | PairCorr |
| 0.8 | BHC | Bausch Health Companies | PairCorr |
| 0.74 | GANX | Gain Therapeutics | PairCorr |
| 0.69 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.